Gene info: ID 6868

Gene: ADAM17

GENE ID: 6868

Description: ADAM metallopeptidase domain 17

Gene type: protein-coding

Location: 2p25.1

dbXrefs: Ensembl:ENSG00000151694 MIM:603639 Vega:OTTHUMG00000090425 UniprotKB:P78536

RefSeq: NG_029873.1

Retrived from: PubMed|SNP Mapped

SNPs: 1 ANCO-SNPs

Phenotype: ND|AD

# Publications: 3

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 4.220e-1 (AD) 1.946e-3 (ND)

ANCO-SNPs

SNP ID	Position	Alleles	Trait	Variation Type
rs17362650	chr2:9536284 (GRCh38.p7)	T>C	alcohol dependence	SNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
TSTD2	0.899
GPATCH8	0.878
MLLT10	0.876
NUP153	0.875
ATXN7	0.862
M6PR	0.861
PHC1	0.861
ZNF587	0.859
POLH	0.858
RNPC3	0.857

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
OR4F5	-0.417
OR4F29	-0.384
KLRC3	-0.329
KLRC2	-0.327
APOA1	-0.298
S100A1	-0.294
NANOGNB	-0.268
BCL7C	-0.263
MTRNR2L10	-0.246
TRDN	-0.239

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB06943	(3S)-1-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}pyrrolidine-3-thiol	Small Molecule	-	Experimental	Target
DB07079	3-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}propane-1-thiol	Small Molecule		Experimental	Target
DB07121	4-({4-[(4-AMINOBUT-2-YNYL)OXY]PHENYL}SULFONYL)-N-HYDROXY-2,2-DIMETHYLTHIOMORPHOLINE-3-CARBOXAMIDE	Small Molecule		Experimental	Target
DB07145	(2R)-N-HYDROXY-2-[(3S)-3-METHYL-3-{4-[(2-METHYLQUINOLIN-4-YL)METHOXY]PHENYL}-2-OXOPYRROLIDIN-1-YL]PROPANAMIDE	Small Molecule		Experimental	Target
DB07147	methyl (1R,2S)-2-(hydroxycarbamoyl)-1-{4-[(2-methylquinolin-4-yl)methoxy]benzyl}cyclopropanecarboxylate	Small Molecule		Experimental	Target
DB07189	(1S,3R,6S)-4-oxo-6-{4-[(2-phenylquinolin-4-yl)methoxy]phenyl}-5-azaspiro[2.4]heptane-1-carboxylic acid	Small Molecule		Experimental	Target
DB07233	N-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}-5-methyl-D-tryptophan	Small Molecule		Experimental	Target
DB07964	(3S)-4-{[4-(BUT-2-YNYLOXY)PHENYL]SULFONYL}-N-HYDROXY-2,2-DIMETHYLTHIOMORPHOLINE-3-CARBOXAMIDE	Small Molecule		Experimental	Target

ID	Drug Name	Action	PubMed
C023514	2,6-dinitrotoluene	"2,6-dinitrotoluene affects the expression of ADAM17 mRNA"	21346803
C499807	(2R, 3S)-2-(((4-(2-butynyloxy)phenyl)sulfonyl)amino)-N,3-dihydroxybutanamide	"(2R, 3S)-2-(((4-(2-butynyloxy)phenyl)sulfonyl)amino)-N,3-dihydroxybutanamide results in decreased activity of ADAM17 protein"	19875451
C023035	3,4,5,3',4'-pentachlorobiphenyl	"3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of ADAM17 mRNA"	23196670
C009505	4,4'-diaminodiphenylmethane	"4,4'-diaminodiphenylmethane results in increased expression of ADAM17 mRNA"	18648102
C041594	4-nonylphenol	ADAM10 protein affects the reaction [ADAM17 protein affects the reaction [4-nonylphenol results in increased secretion of HBEGF protein]]	28703301
C041594	4-nonylphenol	ADAM10 protein affects the reaction [ADAM17 protein affects the reaction [4-nonylphenol results in increased secretion of TGFA protein]]	28703301
C041594	4-nonylphenol	ADAM10 protein affects the reaction [[ADAM17 protein affects the susceptibility to 4-nonylphenol] which affects the secretion of BTC protein]	28703301
C041594	4-nonylphenol	ADAM17 protein affects the reaction [4-nonylphenol results in increased secretion of HBEGF protein]	28703301
C041594	4-nonylphenol	ADAM17 protein affects the reaction [4-nonylphenol results in increased secretion of TGFA protein]	28703301
C041594	4-nonylphenol	ADAM17 protein affects the susceptibility to 4-nonylphenol	28703301
C041594	4-nonylphenol	[ADAM17 protein affects the susceptibility to 4-nonylphenol] which affects the secretion of BTC protein	28703301
C056498	aceclofenac	ADAM17 results in increased susceptibility to aceclofenac	12147693
D000082	Acetaminophen	Acetaminophen results in decreased expression of ADAM17 mRNA	26690555
D000082	Acetaminophen	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ADAM17 mRNA	25607892
D000171	Acrolein	ADAM17 protein promotes the reaction [Acrolein results in increased expression of MUC5AC mRNA]	15531749
D020106	Acrylamide	Acrylamide results in decreased expression of ADAM17 mRNA	28959563
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of ADAM17 mRNA	16483693
D000726	Androgen Antagonists	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ADAM17 mRNA	25607892
D018501	Antirheumatic Agents	Antirheumatic Agents results in decreased expression of ADAM17 mRNA	24449571
C484302	apratastat	apratastat results in decreased activity of ADAM17 protein	19875451
D001151	Arsenic	Arsenic results in decreased expression of ADAM17 mRNA	11134558
D000069059	Atorvastatin Calcium	Atorvastatin Calcium results in decreased expression of ADAM17 protein	18360054
D001280	Atrazine	Atrazine results in increased expression of ADAM17 mRNA	22378314
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of ADAM17 mRNA"	20018196
D004958	Estradiol	[Progesterone co-treated with Estradiol] results in decreased expression of ADAM17 mRNA	18692832
D001688	Biological Products	Biological Products affects the localization of ADAM17 protein	23041113
D001688	Biological Products	Biological Products results in decreased expression of ADAM17 mRNA	23041113
D001688	Biological Products	Biological Products results in decreased expression of ADAM17 protein	23041113
C006780	bisphenol A	bisphenol A results in decreased expression of ADAM17 mRNA	20678512
C006780	bisphenol A	ADAM10 protein affects the reaction [ADAM17 protein affects the reaction [bisphenol A results in increased secretion of HBEGF protein]]	28703301
C006780	bisphenol A	ADAM17 protein affects the reaction [bisphenol A results in increased secretion of HBEGF protein]	28703301
C006780	bisphenol A	[ADAM17 protein co-treated with ADAM10 protein] affects the reaction [bisphenol A results in increased secretion of TGFA protein]	28703301
C006780	bisphenol A	bisphenol A results in increased expression of ADAM17 mRNA	21932408\|2606340
C006780	bisphenol A	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ADAM17 mRNA	25607892
C006780	bisphenol A	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of ADAM17 mRNA	25607892
C006780	bisphenol A	bisphenol A results in increased expression of ADAM17 mRNA	25181051
C000611646	bisphenol F	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ADAM17 mRNA	28628672
D001761	Bleomycin	Bleomycin results in increased expression of and results in increased activity of ADAM17 protein	22687607
C038091	butylparaben	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ADAM17 mRNA	25607892
C038091	butylparaben	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of ADAM17 mRNA	25607892
D020148	Butyric Acid	Butyric Acid results in increased expression of ADAM17 mRNA	12800193
D002122	Calcium Chloride	Calcium Chloride results in increased expression of ADAM17 mRNA	20621845
D002122	Calcium Chloride	Calcium Chloride results in increased expression of ADAM17 protein	20621845
C011724	cholest-5-en-3 beta,7 alpha-diol	"cholest-5-en-3 beta,7 alpha-diol results in decreased activity of ADAM17 protein"	15591071
C018021	cobaltous chloride	cobaltous chloride results in decreased expression of ADAM17 mRNA	19376846
D003300	Copper	[NSC 689534 binds to Copper] which results in increased expression of ADAM17 mRNA	20971185
D019327	Copper Sulfate	Copper Sulfate results in decreased expression of ADAM17 mRNA	20599845
D019327	Copper Sulfate	Copper Sulfate results in increased expression of ADAM17 mRNA	19549813
D003474	Curcumin	Curcumin inhibits the reaction [TNF protein results in increased expression of ADAM17 mRNA]	17666914
D016572	Cyclosporine	Cyclosporine results in increased expression of ADAM17 mRNA	20106945\|2556210
D003907	Dexamethasone	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ADAM17 mRNA	28628672
D003907	Dexamethasone	Dexamethasone results in decreased expression of ADAM17 mRNA	14618091
D016264	Dextran Sulfate	ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of SIRT1 mRNA]	24548422
D016264	Dextran Sulfate	ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of TIMP3 mRNA]	24548422
D016264	Dextran Sulfate	ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IFNG protein]	24548422
D016264	Dextran Sulfate	ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL17A protein]	24548422
D016264	Dextran Sulfate	ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL1B protein]	24548422
D016264	Dextran Sulfate	ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 protein]	24548422
D016264	Dextran Sulfate	ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of TNF protein]	24548422
D016264	Dextran Sulfate	ADAM17 protein affects the susceptibility to Dextran Sulfate	24548422
D016264	Dextran Sulfate	Dextran Sulfate results in increased expression of ADAM17 mRNA	24548422
D016264	Dextran Sulfate	resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of ADAM17 mRNA]	24548422
D003976	Diazinon	Diazinon affects the expression of ADAM17 mRNA	22546817
C000944	dicrotophos	dicrotophos results in decreased expression of ADAM17 mRNA	28302478
D004026	Dieldrin	Dieldrin affects the expression of ADAM17 mRNA	22546817
D004041	Dietary Fats	Dietary Fats results in increased expression of ADAM17 mRNA	25016146
D004391	Dust	Dust results in increased expression of ADAM17 mRNA	17805423
C038939	enzacamene	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ADAM17 mRNA	25607892
C038939	enzacamene	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of ADAM17 mRNA	25607892
D000431	Ethanol	Ethanol results in decreased expression of ADAM17 mRNA	17920746
D004997	Ethinyl Estradiol	Ethinyl Estradiol affects the expression of ADAM17 mRNA	17555576
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of ADAM17 mRNA	17942748
D004997	Ethinyl Estradiol	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of ADAM17 mRNA	17942748
D004997	Ethinyl Estradiol	Ethinyl Estradiol affects the expression of ADAM17 mRNA	23550701
D005020	Ethyl Methanesulfonate	Ethyl Methanesulfonate results in increased expression of ADAM17 mRNA	23649840
C001209	fenamic acid	ADAM17 results in increased susceptibility to fenamic acid	12147693
D005439	Flufenamic Acid	ADAM17 results in increased susceptibility to Flufenamic Acid	12147693
C546771	gardiquimod	gardiquimod results in increased expression of ADAM17 mRNA	28003376
C546771	gardiquimod	Protein Kinase Inhibitors inhibits the reaction [gardiquimod results in increased expression of ADAM17 mRNA]	28003376
C056507	gemcitabine	ADAM17 protein promotes the reaction [gemcitabine results in increased cleavage of AREG protein]	20726858
D005839	Gentamicins	Gentamicins results in increased expression of ADAM17 mRNA	22061828
D005944	Glucosamine	Glucosamine inhibits the reaction [IL1B results in increased expression of ADAM17 mRNA]	17109745
D005944	Glucosamine	Glucosamine results in increased expression of ADAM17 mRNA	17109745
D005944	Glucosamine	IL1B affects the reaction [Glucosamine results in increased expression of ADAM17 mRNA]	17109745
C492546	GW280264X	GW280264X results in decreased activity of ADAM17 protein	19875451
D007213	Indomethacin	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ADAM17 mRNA	28628672
D015759	Ionomycin	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of ADAM17 mRNA	25613284
D015056	1-Methyl-3-isobutylxanthine	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ADAM17 mRNA	28628672
C440499	lipopolysaccharide, Escherichia coli O111 B4	"lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of ADAM17 protein"	26298005
C440499	lipopolysaccharide, Escherichia coli O111 B4	"Methylthiouracil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of ADAM17 protein]"	26298005
D008070	Lipopolysaccharides	Lipopolysaccharides results in increased expression of ADAM17	21874253
D008070	Lipopolysaccharides	TLR4 mutant form promotes the reaction [Lipopolysaccharides results in increased expression of ADAM17]	21874253
D008555	Melitten	Melitten results in increased cleavage of and results in increased activity of ADAM17 protein	22613720
D008741	Methyl Methanesulfonate	Methyl Methanesulfonate results in increased expression of ADAM17 mRNA	23649840
D018817	N-Methyl-3,4-methylenedioxyamphetamine	"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of ADAM17 mRNA"	20188158
D015655	1-Methyl-4-phenylpyridinium	U 0126 affects the reaction [1-Methyl-4-phenylpyridinium affects the expression of ADAM17 mRNA]	12710931
D008779	Methylthiouracil	"Methylthiouracil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of ADAM17 protein]"	26298005
D008779	Methylthiouracil	Methylthiouracil inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ADAM17 protein]	26298005
C580583	N6L peptide	[N6L peptide results in increased secretion of TIMP3 protein] which results in decreased activity of ADAM17 protein	23109338
D009525	Niacin	Niacin results in increased expression of ADAM17 protein	19223914
C022838	nickel chloride	nickel chloride affects the expression of ADAM17 mRNA	22546817
C558013	NSC 689534	[NSC 689534 binds to Copper] which results in increased expression of ADAM17 mRNA	20971185
C118580	octylmethoxycinnamate	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ADAM17 mRNA	25607892
C118580	octylmethoxycinnamate	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of ADAM17 mRNA	25607892
D010098	Oxycodone	Oxycodone results in decreased expression of ADAM17 mRNA	23439660
D052638	Particulate Matter	ADAM17 mutant form inhibits the reaction [Particulate Matter results in increased secretion of CSF2 protein]	22581348
C023036	perfluorooctanoic acid	perfluorooctanoic acid results in decreased expression of ADAM17 mRNA	19162173
D010634	Phenobarbital	Phenobarbital affects the expression of ADAM17 mRNA	19159669
D010656	Phenylephrine	ADAM17 protein affects the reaction [Phenylephrine results in increased cleavage of and results in increased secretion of EGF protein]	16760267
D010656	Phenylephrine	ADAM17 protein affects the reaction [Phenylephrine results in increased phosphorylation of MAPK1 protein]	16760267
D010656	Phenylephrine	ADAM17 protein affects the reaction [Phenylephrine results in increased phosphorylation of MAPK3 protein]	16760267
D010936	Plant Extracts	Plant Extracts results in increased expression of ADAM17 mRNA	23557933
D011374	Progesterone	[Progesterone co-treated with Estradiol] results in decreased expression of ADAM17 mRNA	18692832
D011374	Progesterone	Progesterone results in decreased expression of ADAM17 mRNA	18692832
C045950	propiconazole	propiconazole results in increased expression of ADAM17 mRNA	21278054
D047428	Protein Kinase Inhibitors	Protein Kinase Inhibitors inhibits the reaction [gardiquimod results in increased expression of ADAM17 mRNA]	28003376
C059514	resveratrol	resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of ADAM17 mRNA]	24548422
C041376	rosmarinic acid	rosmarinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ADAM17 protein]	23774263
C041376	rosmarinic acid	[rosmarinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ADAM17 protein]] which affects the localization of PROCR protein	23774263
C041376	rosmarinic acid	[rosmarinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ADAM17 protein]] which results in decreased cleavage of and results in decreased secretion of PROCR protein	23774263
C041376	rosmarinic acid	rosmarinic acid results in decreased expression of ADAM17 protein	23774263
C041376	rosmarinic acid	[rosmarinic acid results in decreased expression of ADAM17 protein] inhibits the reaction [IL1B protein affects the localization of PROCR protein]	23774263
C041376	rosmarinic acid	[rosmarinic acid results in decreased expression of ADAM17 protein] inhibits the reaction [IL1B protein results in increased cleavage of and results in increased secretion of PROCR protein]	23774263
C041376	rosmarinic acid	[rosmarinic acid results in decreased expression of ADAM17 protein] inhibits the reaction [TNF protein affects the localization of PROCR protein]	23774263
C041376	rosmarinic acid	[rosmarinic acid results in decreased expression of ADAM17 protein] inhibits the reaction [TNF protein results in increased cleavage of and results in increased secretion of PROCR protein]	23774263
C009277	sodium arsenate	sodium arsenate results in increased expression of ADAM17 mRNA	21795629
C017947	sodium arsenite	sodium arsenite results in decreased expression of ADAM17 mRNA	28595984
D013629	Tamoxifen	Tamoxifen affects the expression of ADAM17 mRNA	17555576
C099410	TAPI-2	TAPI-2 results in decreased activity of ADAM17 protein	22820758
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of ADAM17 mRNA	21570461
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of ADAM17 mRNA	17942748
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of ADAM17 mRNA	17942748
D013755	Tetradecanoylphorbol Acetate	Methylthiouracil inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ADAM17 protein]	26298005
D013755	Tetradecanoylphorbol Acetate	rosmarinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ADAM17 protein]	23774263
D013755	Tetradecanoylphorbol Acetate	[rosmarinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ADAM17 protein]] which affects the localization of PROCR protein	23774263
D013755	Tetradecanoylphorbol Acetate	[rosmarinic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ADAM17 protein]] which results in decreased cleavage of and results in decreased secretion of PROCR protein	23774263
D013755	Tetradecanoylphorbol Acetate	Tetradecanoylphorbol Acetate promotes the reaction [ADAM17 protein results in increased cleavage of PROCR protein]	24632454
D013755	Tetradecanoylphorbol Acetate	Tetradecanoylphorbol Acetate results in increased expression of ADAM17 protein	23774263\|2629800
D013755	Tetradecanoylphorbol Acetate	Tetradecanoylphorbol Acetate results in increased expression of and results in increased activity of ADAM17 protein	24632454
D013755	Tetradecanoylphorbol Acetate	withaferin A inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [ADAM17 protein results in increased cleavage of PROCR protein]]	24632454
D013755	Tetradecanoylphorbol Acetate	withaferin A inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased activity of ADAM17 protein]	24632454
D013755	Tetradecanoylphorbol Acetate	ADAM17 protein affects the reaction [Tetradecanoylphorbol Acetate results in increased secretion of HBEGF protein]	28703301
D013755	Tetradecanoylphorbol Acetate	ADAM17 protein affects the reaction [Tetradecanoylphorbol Acetate results in increased secretion of TGFA protein]	28703301
D013755	Tetradecanoylphorbol Acetate	ADAM17 results in increased susceptibility to Tetradecanoylphorbol Acetate	12147693
D013755	Tetradecanoylphorbol Acetate	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of ADAM17 mRNA	25613284
D013853	Thioacetamide	Thioacetamide results in increased expression of ADAM17 mRNA	23411599
D014212	Tretinoin	Tretinoin affects the localization of ADAM17 protein	19476501
D014212	Tretinoin	Tretinoin affects the localization of ADAM17 protein	19476501
C016805	tris(1,3-dichloro-2-propyl)phosphate	"tris(1,3-dichloro-2-propyl)phosphate results in increased expression of ADAM17 mRNA"	26179874
C113580	U 0126	U 0126 affects the reaction [1-Methyl-4-phenylpyridinium affects the expression of ADAM17 mRNA]	12710931
D014635	Valproic Acid	Valproic Acid results in decreased expression of ADAM17 mRNA	23179753
D014635	Valproic Acid	Valproic Acid results in increased expression of ADAM17 mRNA	29154799
D014638	Vanadates	Vanadates results in increased expression of ADAM17 mRNA	22714537
D014639	Vanadium	Vanadium results in increased expression of ADAM17 mRNA	19000753
C025643	vinclozolin	vinclozolin affects the expression of ADAM17 mRNA	19015723
D014800	Vitallium	Vitallium analog results in increased expression of ADAM17 mRNA	23825117
D014810	Vitamin E	Vitamin E results in decreased expression of ADAM17 mRNA	19244175
C009684	withaferin A	withaferin A inhibits the reaction [IL1B protein promotes the reaction [ADAM17 protein results in increased cleavage of PROCR protein]]	24632454
C009684	withaferin A	withaferin A inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [ADAM17 protein results in increased cleavage of PROCR protein]]	24632454
C009684	withaferin A	withaferin A inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased activity of ADAM17 protein]	24632454
C009684	withaferin A	withaferin A inhibits the reaction [TNF protein promotes the reaction [ADAM17 protein results in increased cleavage of PROCR protein]]	24632454
C088658	zoledronic acid	ADAM17 protein promotes the reaction [zoledronic acid results in decreased expression of TNFSF11 protein]	14753746
C088658	zoledronic acid	zoledronic acid results in decreased activity of ADAM17 protein	14753746
C088658	zoledronic acid	zoledronic acid results in increased expression of ADAM17 protein	14753746

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0004222	metalloendopeptidase activity	-	IDA	9920899 24226769
GO:0004222	metalloendopeptidase activity	-	IMP	9034190 9034191
GO:0004222	metalloendopeptidase activity	-	TAS	-
GO:0005112	Notch binding	-	IDA	24226769
GO:0005138	interleukin-6 receptor binding	-	IPI	16034137
GO:0005178	integrin binding	-	IPI	14970227
GO:0005515	protein binding	-	IPI	10527948 12668732 15280379 18355445 18625725 18638486 22246777
GO:0008237	metallopeptidase activity	-	IDA	12777399
GO:0008237	metallopeptidase activity	-	IMP	12535668
GO:0008237	metallopeptidase activity	-	TAS	-
GO:0017124	SH3 domain binding	-	IEA	-
GO:0030165	PDZ domain binding	-	IPI	12207026
GO:0046872	metal ion binding	-	IEA	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0001666	response to hypoxia	-	IDA	18276953
GO:0001934	positive regulation of protein phosphorylation	-	IMP	18625725
GO:0002446	neutrophil mediated immunity	-	IC	16034137
GO:0002467	germinal center formation	-	ISS	10433800
GO:0002690	positive regulation of leukocyte chemotaxis	-	IC	16034137
GO:0006508	proteolysis	-	IDA	24227843
GO:0006509	membrane protein ectodomain proteolysis	-	IDA	9034190 9574564 17786981 18676862
GO:0006509	membrane protein ectodomain proteolysis	-	IMP	9034191 12743035 16034137 18373975 21170088
GO:0007155	cell adhesion	-	IDA	14970227
GO:0007173	epidermal growth factor receptor signaling pathway	-	IDA	12743035
GO:0007219	Notch signaling pathway	-	IEA	-
GO:0007220	Notch receptor processing	-	IDA	24226769
GO:0008284	positive regulation of cell proliferation	-	IMP	18373975
GO:0010820	positive regulation of T cell chemotaxis	-	IMP	18373975
GO:0030183	B cell differentiation	-	ISS	10433800
GO:0030307	positive regulation of cell growth	-	IMP	18373975
GO:0030335	positive regulation of cell migration	-	IMP	18373975
GO:0030511	positive regulation of transforming growth factor beta receptor signaling pathway	-	ISS	10433800
GO:0030512	negative regulation of transforming growth factor beta receptor signaling pathway	-	IMP	21170088
GO:0031293	membrane protein intracellular domain proteolysis	-	TAS	-
GO:0031659	positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle	-	IDA	18483258
GO:0032496	response to lipopolysaccharide	-	IDA	18383040
GO:0032722	positive regulation of chemokine production	-	IMP	16034137
GO:0033025	regulation of mast cell apoptotic process	-	ISS	10433800
GO:0033077	T cell differentiation in thymus	-	ISS	10433800
GO:0033209	tumor necrosis factor-mediated signaling pathway	-	TAS	-
GO:0033627	cell adhesion mediated by integrin	-	IDA	14970227
GO:0035313	wound healing, spreading of epidermal cells	-	IEP	14970227
GO:0035625	epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway	-	IMP	17655843
GO:0042493	response to drug	-	ISS	10433800
GO:0043536	positive regulation of blood vessel endothelial cell migration	-	IDA	24813629
GO:0045741	positive regulation of epidermal growth factor-activated receptor activity	-	IDA	18483258
GO:0045741	positive regulation of epidermal growth factor-activated receptor activity	-	IMP	17655843
GO:0048536	spleen development	-	ISS	10433800
GO:0048870	cell motility	-	ISS	10433800
GO:0050830	defense response to Gram-positive bacterium	-	IMP	16034137
GO:0051088	PMA-inducible membrane protein ectodomain proteolysis	-	IDA	14625290 15691827 17010968
GO:0051088	PMA-inducible membrane protein ectodomain proteolysis	-	IMP	18676862
GO:0051272	positive regulation of cellular component movement	-	ISS	10433800
GO:0071403	cellular response to high density lipoprotein particle stimulus	-	IDA	17786981
GO:1903265	positive regulation of tumor necrosis factor-mediated signaling pathway	-	IMP	24813629
GO:1905564	positive regulation of vascular endothelial cell proliferation	-	IDA	24813629

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005737	cytoplasm	-	IDA	25468996
GO:0005829	cytosol	-	IDA	-
GO:0005886	plasma membrane	-	TAS	-
GO:0005887	integral component of plasma membrane	-	IDA	17786981
GO:0005911	cell-cell junction	colocalizes_with	IDA	14970227
GO:0005925	focal adhesion	colocalizes_with	IDA	14970227
GO:0009986	cell surface	-	IDA	9034190 18383040 18625725
GO:0015629	actin cytoskeleton	-	IDA	17010968
GO:0016020	membrane	-	HDA	19946888
GO:0016324	apical plasma membrane	-	IDA	16034137
GO:0032587	ruffle membrane	colocalizes_with	IDA	14970227
GO:0045121	membrane raft	-	IDA	17010968 17786981

KEGG ID	KEGG Term
hsa04330	Notch signaling pathway
hsa05010	Alzheimer's disease
hsa05120	Epithelial cell signaling in Helicobacter pylori infection

Reactome ID	Reactome Term	Evidence
R-HSA-1236394	Signaling by ERBB4	IEA
R-HSA-1251985	Nuclear signaling by ERBB4	IEA
R-HSA-1280215	Cytokine Signaling in Immune system	IEA
R-HSA-1442490	Collagen degradation	IEA
R-HSA-1474228	Degradation of the extracellular matrix	IEA
R-HSA-1474244	Extracellular matrix organization	IEA
R-HSA-157118	Signaling by NOTCH	IEA
R-HSA-162582	Signal Transduction	IEA
R-HSA-162582	Signal Transduction	TAS
R-HSA-1643685	Disease	TAS
R-HSA-168256	Immune System	IEA
R-HSA-177929	Signaling by EGFR	IEA
R-HSA-193692	Regulated proteolysis of p75NTR	TAS
R-HSA-193704	p75 NTR receptor-mediated signalling	TAS
R-HSA-1980143	Signaling by NOTCH1	IEA
R-HSA-2122948	Activated NOTCH1 Transmits Signal to the Nucleus	IEA
R-HSA-2644602	Signaling by NOTCH1 PEST Domain Mutants in Cancer	TAS
R-HSA-2644603	Signaling by NOTCH1 in Cancer	TAS
R-HSA-2644606	Constitutive Signaling by NOTCH1 PEST Domain Mutants	TAS
R-HSA-2660825	Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant	TAS
R-HSA-2660826	Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant	TAS
R-HSA-2691230	Signaling by NOTCH1 HD Domain Mutants in Cancer	TAS
R-HSA-2691232	Constitutive Signaling by NOTCH1 HD Domain Mutants	TAS
R-HSA-2894858	Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer	TAS
R-HSA-2894862	Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants	TAS
R-HSA-5358346	Hedgehog ligand biogenesis	IEA
R-HSA-5358351	Signaling by Hedgehog	IEA
R-HSA-5362798	Release of Hh-Np from the secreting cell	IEA
R-HSA-5663202	Diseases of signal transduction	TAS
R-HSA-73887	Death Receptor Signalling	TAS
R-HSA-75893	TNF signaling	TAS
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	IEA
R-HSA-982772	Growth hormone receptor signaling	IEA

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
28631723	Pharmacogenetic biomarkers of response in Crohn's disease. (2018 Jan)	Linares-Pineda TM	Pharmacogenomics J
24687274	Association between serum soluble low-density lipoprotein receptor levels and metabolic factors in healthy Japanese individuals. (2015 Jan)	Shimohiro H	J Clin Lab Anal
27222041	A proteomic signature of ovarian cancer tumor fluid identified by highthroughput and verified by targeted proteomics. (2016 Aug 11)	Poersch A	J Proteomics